Overview
- CMS published Maximum Fair Prices for 15 widely used Part D medicines to take effect January 1, 2027, covering treatments for diabetes, cancer, asthma and more.
- Semaglutide products Ozempic and Rybelsus are priced at about $274 for a 30‑day supply, with Wegovy’s highest dose at about $385, according to the negotiated rates.
- The agency projects roughly $12 billion in Medicare savings and about $685 million in beneficiary out-of-pocket reductions, while a separate analysis cited $8.5 billion, or 36%, versus last year’s spending.
- The drugs were used by about 5.3 million Part D enrollees in 2024 and accounted for roughly $42.5 billion in spending, bringing the total number of negotiated drugs to 25 as another round begins next year.
- Negotiated prices reflect what Medicare pays manufacturers, not pharmacy counter costs, and patient bills will still depend on plan formularies, coinsurance, rebates and the roughly $2,200 Part D out-of-pocket cap expected in 2027.